Vividion Therapeutics, Inc.

Precision Science Inspired by Human Biology

Add To Watchlist
General Information
Company Name
Vividion Therapeutics, Inc.
Founded Year
2017
Location (Offices)
San Diego, United States
Founders / Decision Makers
Shawn Rose - Chief Development Officer (CDO), Immunology Diego Miralles - CEO Jean Bemis - Senior Vice President of Operations and Alliances Jin-Quan Yu - Founder Patricia Allen - Chief Financial Officer Phil Baran - Founder
Number of Employees
251
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Series C
Social Media

Vividion Therapeutics, Inc. - Company Profile

Vividion Therapeutics, Inc. is a biotechnology company founded in 2013, with a mission to revolutionize human health by developing highly selective small molecule medicines that target traditionally inaccessible proteins. The company's innovative platform, initiated by scientists from The Scripps Research Institute, specializes in oncology and immunology. With a strong emphasis on precision science and inspired by human biology, Vividion is advancing a diverse pipeline of selective small molecule therapeutics. The company recently secured a significant $135.00M Series C investment on 24 February 2021, with participation from prominent investors including Boxer Capital, T. Rowe Price, Acuta Capital, Avoro Capital, Driehaus Capital Management, Logos Capital, Nextech Invest, SoftBank Vision Fund, Woodline Partners, and Surveyor Capital. Headquartered in the United States, Vividion Therapeutics, Inc. epitomizes innovation and dedication in the biotechnology and healthcare industries, poised to make a substantial impact on the future of medicine.

Taxonomy: small molecule medicines, selective therapeutics, oncology, immunology, chemical biology, proteomic chemistry, drug discovery, target discovery, synthetic chemistry, transformative therapeutics

Funding Rounds & Investors of Vividion Therapeutics, Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Series C $135.00M 10
Boxer Capital, investor in Vividion Therapeutics, Inc.'s Series C round T. Rowe Price, investor in Vividion Therapeutics, Inc.'s Series C round Avoro Capital, investor in Vividion Therapeutics, Inc.'s Series C round Driehaus Capital Management, investor in Vividion Therapeutics, Inc.'s Series C round Logos Capital, investor in Vividion Therapeutics, Inc.'s Series C round Nextech Invest, investor in Vividion Therapeutics, Inc.'s Series C round SoftBank Vision Fund, investor in Vividion Therapeutics, Inc.'s Series C round Woodline Partners, investor in Vividion Therapeutics, Inc.'s Series C round
Acuta Capital Partners, Surveyor Capital 		24 Feb 2021
Series B $82.00M - 30 Apr 2019
Corporate Round $101.00M - 05 Mar 2018
Series A $50.00M - 02 Feb 2017
Series A $3.50M - 11 Apr 2016

Latest News of Vividion Therapeutics, Inc.

View All

No recent news or press coverage available for Vividion Therapeutics, Inc..

Similar Companies to Vividion Therapeutics, Inc.

View All
1859 - Similar company to Vividion Therapeutics, Inc.
1859 The Origin of Next Generation Medicines
RAPT Therapeutics - Similar company to Vividion Therapeutics, Inc.
RAPT Therapeutics The Science to Overcome Inflammation and Cancer
INVENT Pharmaceuticals - Similar company to Vividion Therapeutics, Inc.
INVENT Pharmaceuticals Transforming molecules to medicines
Degron Therapeutics - Similar company to Vividion Therapeutics, Inc.
Degron Therapeutics Aims to become a global leader in the discovery and development of molecular glue degraders
IpiNovyx Bio - Similar company to Vividion Therapeutics, Inc.
IpiNovyx Bio We are a drug platform focused on treating autoimmune and inflammatory diseases.
Circle Decoration Circle Decoration

Want to dive deeper into Vividion Therapeutics, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now